Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer
Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024
Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program
Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023
Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023
Microvascular Therapeutics Receives $3.98M Award from Department of Defense for Its Cardiovascular Product
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a $3.98M FY22 Technology/Therapeutic Development – Funding Level 2 grant from the Congressionally Directed Medical Research Programs (CDMRP). Emmanuelle Meuillet, Chief... - October 18, 2023
David Lim Joins the Team at Microvascular Therapeutics as Director of Finance
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all... - November 25, 2022
Marty Rosenberg joins the Board of Scientific Advisors at Microvascular Therapeutics.
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for... - November 25, 2022
Microvascular Therapeutics Receives Funds from the National Cancer Institute (NCI) for Its Brain Tumor Program
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are... - November 18, 2022
Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100
Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022
Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100
MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022
Timothy Healey Joins the Board of Director at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022
ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit
ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022
Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022
Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)
Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021
Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Alzheimer Program
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Institute of Aging (NIA), part of the National Institutes of Health (NIH). Wyatt Unger, MD, MBA, President and CEO of MVT said,... - August 03, 2020
Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Program to Treat Heart Attack
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health. Wyatt Unger, MD, MBA, President and CEO of... - July 31, 2020